The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
- Conditions
- HIV SeropositivityBlood DiseaseCancer
- Interventions
- Diagnostic Test: HIV Ag +Ab Assay Kit (Sysmex)
- Registration Number
- NCT05983536
- Lead Sponsor
- Qianfoshan Hospital
- Brief Summary
To evaluate the anti-interference and specificity of HIV Ag +Ab Assay Kit (Sysmex) for the detection of HIV antigens and antibodies.
- Detailed Description
First,HIV Ag +Ab Assay Kit (Sysmex)Assay Kit (Sysmex) was used to detect HIV antigens and antibodies in the serum of patients with tumor and blood diseases, and then confirmed by using the gold standard for HIV diagnosis,human immunodeficiency virus (HIV type 1+2) antibody assay kit (immunoimprinting). The specificity of HIV Ag +Ab Assay Kit (Sysmex) for HIV assay in patients with tumor and hematological diseases was calculated.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 1200
- Clinical diagnosis of tumor Disease or blood disease
- Blood samples must meet the test requirements
- N/A
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients with blood diseases HIV Ag +Ab Assay Kit (Sysmex) Bone marrow aspiration and biopsy confirmed the blood disease Cancer patients HIV Ag +Ab Assay Kit (Sysmex) Cancer patints that confirmed by pathological examination
- Primary Outcome Measures
Name Time Method The HIV Ab/Ag results through study completion, an average of 1.5 year The HIV Ab/Ag results generated using HIV Ag +Ab Assay Kit (Sysmex) and the gold standard method for HIV test. The results will be recoreded seperately.
- Secondary Outcome Measures
Name Time Method